Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Oral ketamine 1 vs 2 mg/kg for treatment-resistant major depressive disorder
IRCT20090801002266N14Phase 3Completed
- Sponsor
- Isfahan University of Medical Sciences
- Start
- Jun 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3 trial of ketamine in major depressive disorder (MDD) (2 arms), sponsored by Isfahan University of Medical Sciences. Started Jun 2020; status: completed.
02
Drugs
ketamine
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on IRCT20090801002266N14.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20090801002266N14.